Lidocaine plus adrenaline — Competitive Intelligence Brief

Lidocaine plus adrenaline (Lidocaine plus adrenaline) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic with vasopressor. Area: Anesthesia/Pain Management.

marketed Local anesthetic with vasopressor Voltage-gated sodium channels; alpha-1 and beta-1 adrenergic receptors Anesthesia/Pain Management Small molecule

Target snapshot

Lidocaine plus adrenaline (Lidocaine plus adrenaline) — University of Santiago de Compostela. Lidocaine blocks sodium channels to provide local anesthesia, while adrenaline (epinephrine) causes vasoconstriction to prolong anesthetic duration and reduce systemic toxicity.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lidocaine plus adrenaline TARGET	Lidocaine plus adrenaline	University of Santiago de Compostela	marketed	Local anesthetic with vasopressor	Voltage-gated sodium channels; alpha-1 and beta-1 adrenergic receptors
Bupivacaine-adrenaline	Bupivacaine-adrenaline	University of Aarhus	marketed	Local anesthetic with vasopressor	Voltage-gated sodium channels; alpha-1 adrenergic receptors (adrenaline component)
Bupivacaine 0.25% with Epinephrine	Bupivacaine 0.25% with Epinephrine	Holy Cross Hospital, Florida	marketed	Local anesthetic with vasopressor	Voltage-gated sodium channels
Bupivicaine + epinephrine	Bupivicaine + epinephrine	Rush University Medical Center	marketed	Local anesthetic with vasopressor	Voltage-gated sodium channels; alpha and beta-adrenergic receptors
Bupivacaine-epinephrine	Bupivacaine-epinephrine	Lumbini Medical College	marketed	Local anesthetic with vasopressor	Voltage-gated sodium channels; alpha-1 and beta-2 adrenergic receptors
Articaine / EPINEPHrine Cartridge	Articaine / EPINEPHrine Cartridge	Universidad de Antioquia	marketed	Local anesthetic with vasopressor	Voltage-gated sodium channels (articaine); alpha-1 and beta-1 adrenergic receptors (epinephrine)
Bupivacaine 0.5 % with Epinephrine	Bupivacaine 0.5 % with Epinephrine	Holy Cross Hospital, Florida	marketed	Local anesthetic with vasopressor	Voltage-gated sodium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic with vasopressor class)

1. Holy Cross Hospital, Florida · 2 drugs in this class
2. Lumbini Medical College · 1 drug in this class
3. Rush University Medical Center · 1 drug in this class
4. Universidad de Antioquia · 1 drug in this class
5. University of Aarhus · 1 drug in this class
6. University of Santiago de Compostela · 1 drug in this class